SG3 Management’s Transmedics TMDX Stock Holding History

SG3 Management’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$166K	–	1247
2021 Q2	$166K	Buy	+5,000	New	+$139K	0.01%	851

Other funds holding TMDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SCP

Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG3 Management's TMDX Position: Q3 2021 in Review

SG3 Management sold out of Transmedics (TMDX) in Q3 2021, closing a stake of 10,000 shares — an estimated $332K sold.

SG3 Management first reported a position in TMDX in Q2 2021 and held it in 1 quarter. The position peaked at $332K in Q2 2021. 120 funds tracked by Wall St. Rank hold TMDX as of Q3 2021.

SG3 Management reported no remaining Transmedics position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 10,000 Transmedics shares in Q3 2021, an estimated $332K.
SG3 Management first reported a position in Transmedics in Q2 2021 and held it in 1 quarter.
SG3 Management's Transmedics position peaked at $332K in Q2 2021.
120 funds tracked by Wall St. Rank held Transmedics as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.